Thermo Fisher Scientific (NYSE:TMO) Reaches New 52-Week High – Here’s Why

Posted by Brenda Bartman on Oct 15th, 2026

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) hit a new 52-week high during trading on Thursday. The stock traded as high as $704.00 and last traded at $684.7180, with a volume of 322,369 shares trading hands. The stock had previously closed at $673.20.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Analysts expect third-quarter revenue and EPS growth, supported by demand for bioproduction products, clinical research services, product innovation and a recovery in biotechnology and pharmaceutical activity. Thermo Fisher to Report Q3 Earnings: What’s in the Cards?
Positive Sentiment: Industry reports point to rapid growth in 3D cell-culture technologies and single-use bioprocessing assemblies—markets expected to expand at approximately 19.9% and 22.8% annually, respectively. Thermo Fisher is listed among the major suppliers positioned to benefit from these trends. Global 3D Cell Culture Technologies Market Report Single-Use Assemblies Global Market Report
Positive Sentiment: Thermo Fisher’s clinical research business is supporting Quantum BioPharma’s Phase 2 multiple-sclerosis trial, highlighting the company’s expanding role across drug development, clinical trials and manufacturing. This provides strategic visibility, although the near-term financial impact is likely limited. Thermo Fisher’s Expanded Drug Lifecycle Role
Neutral Sentiment: Erste Group Bank issued a fiscal 2027 earnings estimate for TMO, while other analyst coverage continues to frame the company as a high-quality life-sciences supplier. The estimate may support valuation confidence, but no specific forecast change was provided. FY2027 Earnings Estimate for TMO Issued By Erste Group Bank
Negative Sentiment: Pre-earnings analysis cautions that Thermo Fisher lacks the combination of positive earnings-revision momentum and other indicators typically associated with a likely earnings beat. With results approaching, this creates downside risk if guidance or demand trends fall short of elevated expectations. Thermo Fisher Scientific Reports Next Week

Analyst Ratings Changes

Several brokerages have issued reports on TMO. TD Cowen lifted their target price on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the stock a “buy” rating in a report on Tuesday. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a report on Monday, July 6th. HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Citigroup downgraded shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. Finally, UBS Group upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $540.00 to $730.00 in a report on Tuesday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $654.05.

View Our Latest Stock Report on TMO

Thermo Fisher Scientific Price Performance

The firm has a 50-day moving average of $633.06 and a 200 day moving average of $545.54. The company has a market capitalization of $254.63 billion, a PE ratio of 37.03, a PEG ratio of 2.77 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Lisa Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $77,982,284.75. This represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds have recently bought and sold shares of the company. Armstrong Advisory Group Inc. grew its position in Thermo Fisher Scientific by 9.0% during the third quarter. Armstrong Advisory Group Inc. now owns 1,095 shares of the medical research company’s stock valued at $739,000 after buying an additional 90 shares during the period. Mirador Capital Partners LP increased its holdings in Thermo Fisher Scientific by 0.4% during the third quarter. Mirador Capital Partners LP now owns 11,916 shares of the medical research company’s stock valued at $8,044,000 after buying an additional 44 shares during the last quarter. Capital Advisors Wealth Management LLC raised its position in Thermo Fisher Scientific by 5.0% in the third quarter. Capital Advisors Wealth Management LLC now owns 775 shares of the medical research company’s stock worth $523,000 after acquiring an additional 37 shares during the period. GK Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth $195,000. Finally, Avity Investment Management Inc. grew its position in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Avity Investment Management Inc. now owns 63,581 shares of the medical research company’s stock valued at $42,920,000 after acquiring an additional 318 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.